Subscribe
Israel-Hamas Conflict
US Immigration
Donald Trump
US Politics
US Economy
Kamala Harris
NFL
Republican Party
Immigration
Volleyball
Soccer
SEC
US Crime
Published

Biogen and Belgian partner UCB announce positive data from late-stage trial of lupus treatment

Summary by MarketWatch
Biogen Inc.’s stock rose 2% early Tuesday, after the company and Belgian partner UCB announced positive results in a late-stage trial

0 Articles

All
Left
Center
Right
The Business JournalsThe Business Journals

Biogen, UCB's lupus drug succeeds in late-stage trial

The promising Phase 3 results come after the lupus drug failed to meet its primary goal in a Phase 2b trial.

·United States
Read Full Article
Financial PostFinancial Post

UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024

Phase 3 PHOENYCS GO study met the primary endpoint demonstrating clinical improvement in moderate-to-severe systemic lupus erythematosus; Clinical improvements were…

·Canada
Read Full Article
MarketWatchMarketWatch

Biogen and Belgian partner UCB announce positive data from late-stage trial of lupus treatment

Biogen Inc.’s stock rose 2% early Tuesday, after the company and Belgian partner UCB announced positive results in a late-stage trial

·United States
Read Full Article
De TijdDe Tijd

UCB makes final push with drug against inflammatory disease lupus

08:05 The pharmaceutical company and its American partner Biogen report good results with a treatment for systemic lupus erythematosus. Both partners have also started a second late-phase study.

·Belgium
Read Full Article
STATSTAT

Risky bet by Biogen and UCB on systemic lupus drug appears to pay off, data show

A Phase 2 study of dapirolizumab pegolin, conducted in 2018, was negative, although the companies saw enough evidence to keep investing in the drug.

·Boston, United States
Read Full Article
stocktitan.netstocktitan.net

UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024

Breakthrough in lupus treatment: UCB and Biogen's dapirolizumab pegol shows promising results in Phase 3 trial. Learn how this novel drug could revolutionize care for moderate-to-severe SLE patients.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 75% of the sources are Center
75% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Similar News Topics

FDAFDA
Stock MarketsStock Markets
Trending Topics
Ground News logo
App Store IconPlay Store Icon
CompanyAboutHistoryMissionBlogTestimonialsGroup SubscriptionsSubscribeGiftFree TrialCareersAffiliates
HelpHelp CenterFAQContact UsFor Educators/LibrariesMedia Bias RatingsOwnership and Factuality RatingsReferral CodeNews SourcesTopics
ToolsAppBrowser ExtensionDaily NewsletterBlindspot Report NewsletterBurst Your Bubble NewsletterTimelines
DonatePrivacy PolicyManage CookiesTerms and Conditions
© 2024 Snapwise Inc
News
For You
Search
BlindspotLocal